Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders.

Authors:
Tsai DH; Bell JS; Abtahi S; Baak BN; Bazelier MT and 30 more

Journal:
Clin Epidemiol

Publication Year: 2023

DOI:
10.2147/CLEP.S426485

PMCID:
PMC10749544

PMID:
38146486

Journal Information

Full Title: Clin Epidemiol

Abbreviation: Clin Epidemiol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Public, Environmental & Occupational Health

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure ECCL reports research funding outside the submitted work from Amgen, Pfizer, Sanofi, Takeda, Roche, IQVIA, the Taiwan National Science and Technology Council (ID:111-2628-B-006-007-) and the Taiwan National Health Research Institutes. EWC reports grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda and the Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region; a honorarium from the Hospital Authority; outside the submitted work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD and Amgen; and personal fees from PrimeVigilance; outside the submitted work. WL reports a research grant from the AIR@InnoHK administered by the Innovation and Technology Commission outside the submitted work. HL has received grants from the Research Grants Council of Hong Kong, outside the submitted work. JSB is supported by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Leadership Fellowship and has received grant funding or consulting funds from the NHMRC, Medical Research Future Fund, Victorian Government Department of Health and Human Services, Dementia Australia Research Foundation, Yulgilbar Foundation, Aged Care Quality and Safety Commission, Dementia Centre for Research Collaboration, Pharmaceutical Society of Australia, Society of Hospital Pharmacists of Australia, GlaxoSmithKline Supported Studies Programme, Amgen and several aged care provider organizations unrelated to this work. All grants and consulting funds were paid to the employing institution. AMT reports research funding outside the submitted work from Amgen. ICKW reports research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, National Institute for Health Research in England, European Commission and the National Health and Medical Research Council in Australia; and is a non-executive director of Jacobson Medical in Hong Kong and a consultant to the World Health Organization. The authors report no other conflicts of interest in this work."

Evidence found in paper:

"Disclosure: ECCL reports research funding outside the submitted work from Amgen, Pfizer, Sanofi, Takeda, Roche, IQVIA, the Taiwan National Science and Technology Council (ID:111-2628-B-006-007-) and the Taiwan National Health Research Institutes. EWC reports grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda and the Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region; a honorarium from the Hospital Authority; outside the submitted work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD and Amgen; and personal fees from PrimeVigilance; outside the submitted work. WL reports a research grant from the AIR@InnoHK administered by the Innovation and Technology Commission outside the submitted work. HL has received grants from the Research Grants Council of Hong Kong, outside the submitted work. JSB is supported by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Leadership Fellowship and has received grant funding or consulting funds from the NHMRC, Medical Research Future Fund, Victorian Government Department of Health and Human Services, Dementia Australia Research Foundation, Yulgilbar Foundation, Aged Care Quality and Safety Commission, Dementia Centre for Research Collaboration, Pharmaceutical Society of Australia, Society of Hospital Pharmacists of Australia, GlaxoSmithKline Supported Studies Programme, Amgen and several aged care provider organizations unrelated to this work. All grants and consulting funds were paid to the employing institution. AMT reports research funding outside the submitted work from Amgen. ICKW reports research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, National Institute for Health Research in England, European Commission and the National Health and Medical Research Council in Australia; and is a non-executive director of Jacobson Medical in Hong Kong and a consultant to the World Health Organization. The authors report no other conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025